Concept Life Sciences, supported by private equity firm Limerston Capital, has acquired Charnwood Discovery, a drug discovery research provider based in Loughborough, Leicestershire. This acquisition aims to enhance Concept Life Sciences' capabilities in delivering advanced scientific solutions and accelerating drug development for its global biotech and pharmaceutical clients.

Charnwood Discovery offers a range of customized drug discovery services and integrated project solutions. Dr. Ben Cliff, CEO of Concept Life Sciences, emphasized that the merger will allow both companies to combine their strengths, significantly speeding up the progression of drug candidates from development to clinical trials, potentially doubling the industry average pace.

Lee Patterson from Charnwood Discovery noted that Concept Life Sciences is recognized for its innovative approach, and the partnership presents opportunities to expand their service portfolio. This collaboration will also provide clients with access to state-of-the-art facilities and leading scientific expertise.

Founded in 1989, Concept Life Sciences is a well-established contract research organization in the UK, serving a diverse clientele in the pharmaceutical and biotechnology sectors. Jane Grewar, operating partner at Limerston Capital and chairman of Concept Life Sciences, expressed excitement about integrating Charnwood's expertise. This integration is expected to enhance their comprehensive offerings and improve timelines for advancing drug candidates to clinical stages, ultimately supporting the delivery of impactful therapies to patients.

Overall, this acquisition positions Concept Life Sciences to better meet the evolving needs of the biotech and pharmaceutical industries, particularly in emerging fields like cell and gene therapies and antibody-drug conjugates.